WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Dec. 20, 2005--Merck & Co., Inc. and the Indian Council of Medical Research (ICMR) announced today a collaboration to study Merck’s investigational cervical cancer vaccine, GARDASIL(R) (quadrivalent human papillomavirus types 6, 11, 16, 18, recombinant vaccine), in developing populations in India. The agreement spans a range of activities, starting with the design of a study to assess the use of GARDASIL in India. In addition to assistance with the study design, Merck will supply GARDASIL for use in the study. Upon completion of the study, the two partners will work together to assess the role of GARDASIL in the population of India and to identify ways of providing access to GARDASIL.
